Home>Topics>Stocks>Acorda Therapeutics

Acorda Therapeutics ACOR

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Next Chapter In The Acorda Story Will Be A Page Turner


      Thu, 10 Apr 2014

      penned his original thoughts on Acorda Therapeutics ( ACOR ) in mid-2013, the stock traded ..... company's $336M net revenue. Acorda is leveraging the dalfampridine ..... post-stroke walking deficits. Acorda 's prospects are improving with

    2. Are Tapeworms The Conceptual Key To The Next Multiple Sclerosis Blockbuster?


      Thu, 10 Apr 2014

      By Richard Richter : Pathogenic infections are understandable. A foreign organism invades your body and you get sick. The immune system eventually takes care of it, sometimes with the help of other drugs. Autoimmune disorders, on the other hand, are much more frustrating. Why would your body ...

    3. From Lab Bench To Bedside: David Lowe Brings Common Sense To Neuroscience Investing


      Sun, 30 Mar 2014

      By Life Sciences Report : Billions of dollars have been spent chasing molecular targets in neurological diseases that now appear to be worthless. Effective therapies remain rare. But the market is enormous-and low risk-if a company can get a truly workable solution to patients. Consultant and ...

    4. Cramer's Mad Money - The Fight Over Sprint Is Just Beginning (4/15/13)


      Tue, 16 Apr 2013

      By SA Editor Miriam Metzinger : Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday April 15. A Fight That Is Just Beginning: Dish Network ( DISH ), Sprint Nextel ( S ), Softbank ( SFTBF.PK ) Dish Network ( DISH ) announced a takeover bid for Sprint ( S ), and ...

    5. We're Boosting Biogen Idec's Fair Value Estimate Following European Approval of Fampyra


      Wed, 27 Jul 2011

      this week. Fampyra, which is marketed in the United States under the trade name Ampyra by the firm's partner Acorda Therapeutics ACOR , is the first approved treatment to improve walking in patients with multiple sclerosis. Fampyra now marks

    6. Acorda shares soar on possible patent extension


      Thu, 14 Apr 2011

      BOSTON (Reuters) - Shares of Acorda Therapeutics Inc jumped 27 percent on Thursday before being halted amid optimism the company will be granted a patent extension on its multiple sclerosis drug...

    7. Squeeze Ideas: 17 Short Seller Targets for a Watchlist


      Fri, 1 Apr 2011

      Kapitall submits: The following is a list of stocks that have experienced a significant increase of short positions from January 28 to February 28. To compile this list we started with a universe of over 700 companies with market caps above $100M. We then sorted our list by the short float and only

    8. Elan's 2010 Results In Line; Enthusiasm for Growth Potential Tempered by High-Risk Pipeline


      Tue, 8 Feb 2011

      EDT) were flat, as patent expirations on older products countered strong manufacturing and royalty revenue from Ampyra, Acorda and Biogen-Idec's BIIB new oral MS drug. Tysabri's net new-patient adds actually fell in the fourth quarter, as compared

    9. Wall Street Breakfast: Must-Know News


      Fri, 31 Dec 2010

      approvals." Among this year's FDA-approval winners: Amgen (AMGN), Roche (RHHBY.PK), Novartis (NVS), Acorda ( ACOR ) and Dendreon (DNDN). Today's Markets In Asia , Japan -1.1% to 10229. Hong Kong +0.2% to 23035. China

    « Prev12Next »
    Content Partners